NASDAQ: TVRD
Tvardi Therapeutics Inc Stock

$24.94+1.94 (+8.43%)
Updated Apr 30, 2025
TVRD Price
$24.94
Fair Value Price
N/A
Market Cap
$114.07M
52 Week Low
$2.71
52 Week High
$26.13
P/E
-1.61x
P/B
-24.83x
P/S
3.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.14M
Earnings
-$70.87M
Gross Margin
91.3%
Operating Margin
-879.81%
Profit Margin
-993%
Debt to Equity
-10.54
Operating Cash Flow
-$61M
Beta
0.64
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

TVRD Overview

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TVRD's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TVRD
Ranked
Unranked of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TVRD news, forecast changes, insider trades & much more!

TVRD News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TVRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TVRD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TVRD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TVRD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TVRD due diligence checks available for Premium users.

Valuation

TVRD fair value

Fair Value of TVRD stock based on Discounted Cash Flow (DCF)

Price
$24.94
Fair Value
$0.14
Overvalued by
18,095.13%
TVRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TVRD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.61x
Industry
-162.28x
Market
29.18x

TVRD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-24.83x
Industry
4.45x

TVRD's financial health

Profit margin

Revenue
$1.5M
Net Income
-$7.7M
Profit Margin
-527.8%
TVRD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TVRD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$43.8M
Liabilities
$48.4M
Debt to equity
-10.54
TVRD's short-term assets ($43.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TVRD's long-term liabilities ($44.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TVRD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TVRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.0M
Investing
$5.0M
Financing
-$1.6M
TVRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TVRD vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TVRD$114.07M+8.43%-1.61x-24.83x
LCTX$113.95M+5.94%-5.54x1.45x
OBIOF$113.79M+17.39%-1.79x3.45x
TNXPD$115.89M+3.51%-0.10x0.83x
ATOSD$115.99M+12.96%-4.49x1.62x

Tvardi Therapeutics Stock FAQ

What is Tvardi Therapeutics's quote symbol?

(NASDAQ: TVRD) Tvardi Therapeutics trades on the NASDAQ under the ticker symbol TVRD. Tvardi Therapeutics stock quotes can also be displayed as NASDAQ: TVRD.

If you're new to stock investing, here's how to buy Tvardi Therapeutics stock.

What is the 52 week high and low for Tvardi Therapeutics (NASDAQ: TVRD)?

(NASDAQ: TVRD) Tvardi Therapeutics's 52-week high was $26.13, and its 52-week low was $2.71. It is currently -4.55% from its 52-week high and 820.97% from its 52-week low.

How much is Tvardi Therapeutics stock worth today?

(NASDAQ: TVRD) Tvardi Therapeutics currently has 4,573,606 outstanding shares. With Tvardi Therapeutics stock trading at $24.94 per share, the total value of Tvardi Therapeutics stock (market capitalization) is $114.07M.

Tvardi Therapeutics stock was originally listed at a price of $154.92 in Jan 31, 2014. If you had invested in Tvardi Therapeutics stock at $154.92, your return over the last 11 years would have been -83.9%, for an annualized return of -15.3% (not including any dividends or dividend reinvestments).

How much is Tvardi Therapeutics's stock price per share?

(NASDAQ: TVRD) Tvardi Therapeutics stock price per share is $24.94 today (as of Apr 30, 2025).

What is Tvardi Therapeutics's Market Cap?

(NASDAQ: TVRD) Tvardi Therapeutics's market cap is $114.07M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tvardi Therapeutics's market cap is calculated by multiplying TVRD's current stock price of $24.94 by TVRD's total outstanding shares of 4,573,606.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.